Cyclacel Pharmaceuticals, Inc.'s Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential And Synergy With Other Anti-Cancer Compounds

Press/Media: Press / Media

PeriodApr 20 2015

Media coverage

1

Media coverage

  • TitleCyclacel Pharmaceuticals, Inc.'s Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential And Synergy With Other Anti-Cancer Compounds
    Media name/outletBioSpace
    CountryUnited States
    Date4/20/15
    PersonsJing Wang